CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance psoriasis treatment by combining Etanercept, a tumor necrosis factor inhibitor, with small interfering RNA targeting IL-17A. Using hybrid lipid-polymer nanoparticles and microneedles, the approach seeks to improve drug delivery and efficacy.
Psoriasis, affecting 2-3% of the global population and 20 million individuals in Europe, poses significant challenges in treatment efficacy and patient adherence to current therapies.
Addressing these challenges, this project proposes an innovative therapeutic strategy by integrating Etanercept (ETR), a TNF- inhibitor, with small interfering RNA (siRNA) targeting IL-17A, facilitated through a novel transdermal delivery method.
The project aims to develop and optimize hybrid lipid-polymer nanopar…
UNIVERSITAIR MEDISCH CENTRUM GRONINGEN
ACADEMISCH ZIEKENHUIS GRONINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
